Literature DB >> 21221621

Prospective, observational study using rabeprazole in 455 patients with laryngopharyngeal reflux disease.

Yoon Se Lee1, Seung-Ho Choi, Young Ik Son, Young-Hak Park, Sang Yoon Kim, Soon Yuhl Nam.   

Abstract

The role of proton pump inhibitor in the treatment of laryngopharygneal reflux disease (LPRD) has been advocated, but there has been few reports dealing with large population based on time-related efficacy of rabeprazole. It was designed to assess the efficacy of rabeprazole and to evaluate which symptoms or findings varied significantly as medication sustained. Multiorgan, open-label cohort, prospective observational study was designed. We identified 1,142 patients with LPRD, and enrolled 455 patients, who participated fully in this survey and follow-up observation for 12 weeks. Reflux symptom index (RSI) and reflux finding score (RFS) were used to evaluate therapeutic efficacy. These parameters were evaluated at the 4th, 8th, and 12th weeks, respectively. Valid rate was used to explain improved proportion of patients after medication. The most common symptom was a globus sense in the throat. Posterior commissure hypertrophy was the most frequently encountered laryngoscopic finding. Female patients complained of heartburn and chest pain more than did male patients (P < 0.001), whereas male patients showed ventricular obliteration and erythematous changes more frequently than did female patients (P < 0.001). By RSI evaluation, scores gradually declined. Each item of the RSI improved at every visit (P < 0.001). Total RFS decreased progressively for 12 weeks and similar results were seen when every RFS item was individually examined. The proportion of patients who showed RSI and RFS falling by more than 50% after medication increased gradually as follow-up continued. This trend seemed to be significant (P < 0.001). Side effects of therapy were minimal. Despite the some constraints of an observational study, rabeprazole appeared to improve LPRD symptoms and signs. Prolonged medication at least 3 months may be beneficial to LPRD patients. Long-term medication effects require further evaluation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21221621     DOI: 10.1007/s00405-010-1475-9

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  29 in total

1.  Double-blind, placebo-controlled trial with esomeprazole for symptoms and signs associated with laryngopharyngeal reflux.

Authors:  Oliver Reichel; Holger Dressel; Katrin Wiederänders; Wolfgang J Issing
Journal:  Otolaryngol Head Neck Surg       Date:  2008-09       Impact factor: 3.497

2.  Efficacy of once-daily esomeprazole treatment in patients with laryngopharyngeal reflux evaluated by 24-hour pH monitoring.

Authors:  Oliver Reichel; Jeanette Keller; Gerd Rasp; Hjalmar Hagedorn; Alexander Berghaus
Journal:  Otolaryngol Head Neck Surg       Date:  2007-02       Impact factor: 3.497

3.  Laryngopharyngeal reflux: prospective cohort study evaluating optimal dose of proton-pump inhibitor therapy and pretherapy predictors of response.

Authors:  Woosuk Park; Douglas M Hicks; Farah Khandwala; Joel E Richter; Tom I Abelson; Claudio Milstein; Michael F Vaezi
Journal:  Laryngoscope       Date:  2005-07       Impact factor: 3.325

4.  The validity and reliability of the reflux finding score (RFS).

Authors:  P C Belafsky; G N Postma; J A Koufman
Journal:  Laryngoscope       Date:  2001-08       Impact factor: 3.325

Review 5.  Review of rabeprazole in the treatment of gastro-oesophageal reflux disease.

Authors:  Bjarni Thjodleifsson
Journal:  Expert Opin Pharmacother       Date:  2004-01       Impact factor: 3.889

6.  Development and validation of a laryngopharyngeal reflux questionnaire, the Pharyngeal Reflux Symptom Questionnaire.

Authors:  Olle Andersson; Anna Rydén; Magnus Ruth; Riitta Ylitalo Möller; Caterina Finizia
Journal:  Scand J Gastroenterol       Date:  2010       Impact factor: 2.423

7.  Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus.

Authors:  Hashem B El-Serag; Thomas V Aguirre; Stephanie Davis; Mark Kuebeler; Achyut Bhattacharyya; Richard E Sampliner
Journal:  Am J Gastroenterol       Date:  2004-10       Impact factor: 10.864

8.  Hoarseness: is it really laryngopharyngeal reflux?

Authors:  Seth M Cohen; C Gaelyn Garrett
Journal:  Laryngoscope       Date:  2008-02       Impact factor: 3.325

9.  Laryngopharyngeal reflux: a prospective analysis of a 34 item symptom questionnaire.

Authors:  L Papakonstantinou; P Leslie; J Gray; T Chadwick; M Hudson; J A Wilson
Journal:  Clin Otolaryngol       Date:  2009-10       Impact factor: 2.597

10.  Validity and reliability of the reflux symptom index (RSI).

Authors:  Peter C Belafsky; Gregory N Postma; James A Koufman
Journal:  J Voice       Date:  2002-06       Impact factor: 2.009

View more
  10 in total

1.  Impact of age on laryngopharyngeal reflux disease presentation: a multi-center prospective study.

Authors:  Jérôme R Lechien; Camille Finck; Kathy Huet; Mohamad Khalife; Anne-Françoise Fourneau; Véronique Delvaux; Myriam Piccaluga; Bernard Harmegnies; Sven Saussez
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-07-17       Impact factor: 2.503

2.  Gender differences in the presentation of dysphonia related to laryngopharyngeal reflux disease: a case-control study.

Authors:  Jérôme R Lechien; Kathy Huet; Mohamad Khalife; Anne-Françoise Fourneau; Camille Finck; Véronique Delvaux; Myriam Piccaluga; Bernard Harmegnies; Sven Saussez
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-03-26       Impact factor: 2.503

3.  Laryngopharyngeal Reflux Disease: Outcome of Patients After Treatment in Otolaryngology Clinics.

Authors:  Montasir Junaid; Sadaf Qadeer Ahmed; Maliha Kazi; Hareem U Khan; Muhammad Sohail Halim
Journal:  Cureus       Date:  2020-12-21

4.  Clinical predictors for response to proton pump inhibitor treatment in patients with globus.

Authors:  Hye Kyung Jeon; Gwang Ha Kim; Mun Ki Choi; Jae Hoon Cheong; Dong Hoon Baek; Gwang Jae Lee; Hang Mi Lee; Bong Eun Lee; Geun Am Song
Journal:  J Neurogastroenterol Motil       Date:  2013-01-08       Impact factor: 4.924

5.  TOPPITS: Trial Of Proton Pump Inhibitors in Throat Symptoms. Study protocol for a randomised controlled trial.

Authors:  Gillian Watson; James O'Hara; Paul Carding; Jan Lecouturier; Deborah Stocken; Tony Fouweather; Janet Wilson
Journal:  Trials       Date:  2016-04-01       Impact factor: 2.279

6.  Prevalence of voice & swallowing complaints in Pre-operative thyroidectomy patients: a prospective cohort study.

Authors:  Theresa Holler; Jennifer Anderson
Journal:  J Otolaryngol Head Neck Surg       Date:  2014-07-15

7.  Impact of laryngopharyngeal reflux on subjective and objective voice assessments: a prospective study.

Authors:  Jérôme R Lechien; Kathy Huet; Mohamad Khalife; Anne-Françoise Fourneau; Véronique Delvaux; Myriam Piccaluga; Bernard Harmegnies; Sven Saussez
Journal:  J Otolaryngol Head Neck Surg       Date:  2016-11-08

8.  Comparison of Characteristics According to Reflux Type in Patients With Laryngopharyngeal Reflux.

Authors:  Jun Seok Lee; Ah Ra Jung; Jung Min Park; Myung Jin Park; Young Chan Lee; Young-Gyu Eun
Journal:  Clin Exp Otorhinolaryngol       Date:  2017-10-11       Impact factor: 3.372

9.  Treatment of laryngopharyngeal reflux disease: A systematic review.

Authors:  Jerome R Lechien; Francois Mouawad; Maria R Barillari; Andrea Nacci; Seyyedeh Maryam Khoddami; Necati Enver; Sampath Kumar Raghunandhan; Christian Calvo-Henriquez; Young-Gyu Eun; Sven Saussez
Journal:  World J Clin Cases       Date:  2019-10-06       Impact factor: 1.337

10.  Use of proton pump inhibitors to treat persistent throat symptoms: multicentre, double blind, randomised, placebo controlled trial.

Authors:  James O'Hara; Deborah D Stocken; Gillian C Watson; Tony Fouweather; Julian McGlashan; Kenneth MacKenzie; Paul Carding; Yakubu Karagama; Ruth Wood; Janet A Wilson
Journal:  BMJ       Date:  2021-01-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.